less invasive, capable of controlling or even curing cancer
In a country where prostate cancer ranks among the most common diagnoses in men, Brazil's Federal Medical Council has taken a measured step toward preserving what illness so often strips away — quality of life. By authorizing high-intensity focused ultrasound and cryoablation as focal therapies, the CFM has acknowledged that precision, not just power, can be a form of healing. The decision does not overturn conventional medicine but carves out space within it for patients whose tumors meet specific criteria to pursue treatment without surrendering sexual and urinary function. It is a reminder that in medicine, as in much of human experience, the question is rarely only whether we can survive, but how.
- For years, men treated for prostate cancer have faced a grim trade-off: survival often came at the cost of incontinence and erectile dysfunction that could last a lifetime.
- Brazil's CFM has now authorized two focal therapies — high-intensity focused ultrasound and cryoablation — that destroy tumors through heat and cold while leaving surrounding nerves and tissue largely intact.
- The authorization is deliberately narrow: only patients with intermediate-favorable, unifocal, unilateral tumors — or select low-risk cases — qualify, and a specialist must confirm eligibility before treatment begins.
- Men with aggressive, high-risk, or intermediate-unfavorable tumors are explicitly excluded, reflecting the council's concern that indiscriminate use could leave some patients dangerously undertreated.
- The real test now lies ahead — whether clinical practice across a vast and uneven healthcare system will honor the careful eligibility boundaries the council has drawn.
Brazil's Federal Medical Council published a resolution on May 27th authorizing two new focal therapies for prostate cancer: high-intensity focused ultrasound, which destroys tumors through heat, and cryoablation, which does so through freezing. Both techniques target cancerous tissue directly while leaving surrounding healthy structures largely untouched — a meaningful departure from conventional approaches that treat the entire gland and frequently leave patients with lasting urinary and sexual complications.
The appeal is rooted in precision. Traditional prostatectomy and radiation often damage the nerves governing continence and sexual function, consequences men may live with for years. Focal therapy, as described by urologist José Elêrton Secioso de Aboim, offers a path to cancer control — and in some cases cure — without that collateral cost. For eligible patients, the difference could be measured not just in survival but in the texture of daily life afterward.
The CFM has been deliberate about limiting the resolution's scope. These techniques are not positioned as replacements for standard care. They apply only to patients with intermediate-favorable risk tumors that are unifocal and unilateral, to those who have already undergone external radiation, and to select low-risk cases. Patients with aggressive or high-risk disease are explicitly excluded. A specialist evaluation is required before any patient proceeds.
That caution reflects a deeper truth about prostate cancer: it is not a single disease. Some tumors are slow-moving and manageable; others demand an aggressive response. Applying focal therapy without discrimination risks undertreating the men who need more. What the council has done is expand the toolkit available to urologists — carefully, conditionally — leaving the harder question of how consistently and faithfully those conditions will be observed in clinics across the country.
Brazil's medical council has cleared the way for two new approaches to treating prostate cancer that promise to spare patients some of the most debilitating side effects of conventional therapy. On Wednesday, May 27th, the CFM—the country's Federal Medical Council—published a resolution authorizing the use of high-intensity focused ultrasound and cryoablation, techniques that destroy cancerous tissue through heat and freezing respectively, while leaving surrounding healthy tissue largely untouched.
The appeal of these focal therapies lies in their precision. Traditional prostate cancer treatment often requires removing or irradiating the entire gland, an approach that frequently leaves men dealing with urinary incontinence and erectile dysfunction for years afterward. The new techniques target only the tumor itself, minimizing collateral damage to the nerves and tissues responsible for sexual and urinary function. José Elêrton Secioso de Aboim, the urologist who reported on the regulation, describes them as less invasive options capable of controlling or even curing cancer while preserving quality of life in ways conventional treatments cannot.
But the council has been careful to draw boundaries around where these treatments can be used. The resolution does not position focal therapy as a replacement for standard care. Instead, it restricts their use to specific patient populations: those with intermediate-favorable risk tumors that are unifocal and unilateral—meaning confined to one side of the gland with lower likelihood of spreading. The techniques can also be applied in patients who have already undergone external radiation therapy, and in select cases of low-risk disease. Patients with intermediate-unfavorable, high-risk, or very-high-risk tumors are explicitly excluded. Any use of these therapies must be recommended by a specialist who can properly assess whether a patient's particular cancer fits the approved criteria.
The distinction matters because prostate cancer is not one disease. Some tumors grow slowly and pose little threat; others are aggressive and require aggressive response. The council's approach reflects an understanding that focal therapy works well for some men but not others, and that applying it indiscriminately could leave some patients undertreated. What the resolution does accomplish is to give urologists and their patients another tool—one that, for the right candidate, might mean avoiding years of sexual dysfunction and incontinence while still achieving cancer control. The question now becomes how quickly these techniques will be adopted in practice, and whether the careful eligibility criteria the council has established will actually be followed in clinical settings across the country.
Notable Quotes
A less invasive technique capable of controlling or even curing cancer with fewer negative impacts on quality of life, especially regarding sexual and urinary function— José Elêrton Secioso de Aboim, urologist and regulation reporter
The Hearth Conversation Another angle on the story
Why did the medical council feel the need to restrict these treatments so carefully? If they're less invasive, shouldn't they be available to more patients?
Because less invasive doesn't mean equally effective for everyone. A focal therapy works by destroying the tumor it can see and reach. If a cancer is already spreading to both sides of the gland or has high-risk features, you might miss disease and give the patient false reassurance while the cancer grows elsewhere.
So it's about matching the tool to the tumor, not just to the patient's preference for fewer side effects.
Exactly. A man with aggressive cancer might accept incontinence and dysfunction as the price of actually being cured. But if you use a gentler technique on him and it fails, you've wasted time and made his situation worse.
What about the men who do qualify? What changes for them?
For them, it's potentially transformative. Imagine being told you have cancer but that your doctors can treat it in a way that lets you keep your sexual function and continence. That's not a small thing. It's the difference between surviving and actually living.
Is there a risk that doctors will use these techniques anyway, even outside the approved criteria?
That's the real question the council is grappling with. They've drawn the lines clearly, but enforcement depends on professional judgment and oversight. The hope is that urologists will respect the boundaries because they understand the reasoning behind them.